Question -Your patient has suffered from schizophrenia for two decadesand has received classic dopaminergic treatments since the onset of illness. The latest research supporting use of the glutamatergic model has not been tried on your patient, and there is an opportunity for your patient to enter clinical trials utilizing glutamate-based treatments. Your patient suffers significant executive function impairment and memory impairment. Do you recommend participation in the clinical trial? Why or why not? Health Science Science Nursing NURS 530A Share QuestionEmailCopy link Comments (0)
Question -Your patient has suffered from schizophrenia for two decadesand has received classic dopaminergic treatments since the onset of illness. The latest research supporting use of the glutamatergic model has not been tried on your patient, and there is an opportunity for your patient to enter clinical trials utilizing glutamate-based treatments. Your patient suffers significant executive function impairment and memory impairment. Do you recommend participation in the clinical trial? Why or why not? Health Science Science Nursing NURS 530A Share QuestionEmailCopy link Comments (0)


